Marathon Capital Management increased its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) by 0.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,360 shares of the pharmaceutical company’s stock after buying an additional 450 shares during the quarter. GlaxoSmithKline PLC accounts for 1.4% of Marathon Capital Management’s investment portfolio, making the stock its 11th largest holding. Marathon Capital Management’s holdings in GlaxoSmithKline PLC were worth $2,991,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also made changes to their positions in GSK. Bronfman E.L. Rothschild L.P. lifted its position in shares of GlaxoSmithKline PLC by 45.4% during the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock valued at $102,000 after buying an additional 753 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its holdings in GlaxoSmithKline PLC by 1,747.4% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock worth $105,000 after purchasing an additional 2,359 shares in the last quarter. Proficio Capital Partners LLC lifted its holdings in GlaxoSmithKline PLC by 233.0% during the 1st quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock worth $122,000 after purchasing an additional 1,990 shares in the last quarter. Heritage Trust Co purchased a new stake in GlaxoSmithKline PLC during the 1st quarter worth about $123,000. Finally, Westwood Holdings Group Inc. lifted its holdings in GlaxoSmithKline PLC by 15.7% during the 1st quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after purchasing an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 9.29% of the company’s stock.
Shares of GlaxoSmithKline PLC (NYSE GSK) traded down 0.42% during mid-day trading on Friday, hitting $40.18. The company had a trading volume of 859,622 shares. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.54. The company has a 50-day moving average price of $39.82 and a 200-day moving average price of $41.78. The company has a market capitalization of $98.20 billion, a price-to-earnings ratio of 39.70 and a beta of 1.03.
GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.02. The business had revenue of $9.36 billion for the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. On average, equities analysts anticipate that GlaxoSmithKline PLC will post $2.87 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be paid a dividend of $0.491 per share. The ex-dividend date is Wednesday, August 9th. This represents a $1.96 dividend on an annualized basis and a yield of 4.87%. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 197.00%.
Several equities analysts have recently commented on the company. Citigroup Inc. lowered GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 5th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday. ValuEngine cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. BidaskClub cut GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Finally, TheStreet cut GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $46.00.
TRADEMARK VIOLATION NOTICE: “GlaxoSmithKline PLC (GSK) Holdings Lifted by Marathon Capital Management” was originally reported by BBNS and is owned by of BBNS. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://baseballnewssource.com/markets/marathon-capital-management-raises-stake-in-glaxosmithkline-plc-gsk/1602878.html.
About GlaxoSmithKline PLC
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with our FREE daily email newsletter.